3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
29
Breast Neoplasms
21
Carcinoma, Non-Small-Cell Lung
20
Triple Negative Breast Neoplasms
15
Lung Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
Esophageal Squamous Cell Carcinoma
7
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Esophageal Neoplasms
5
Ovarian Neoplasms
4
Biliary Tract Neoplasms
4
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Vaccinia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms by Site
2
Neoplasms
2
Locally Advanced Pancreatic Cancer
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Interventions
Carboplatin
5
Nivolumab
4
pembrolizumab
3
Pemetrexed
3
Ipilimumab
3
fludarabine
2
atezolizumab
2
Cyclophosphamide
2
Cisplatin
2
tremelimumab
1
sotorasib
1
osimertinib
1
olaparib
1
durvalumab
1
Tumor Burden
1
Thoracoscopy
1
Tablets
1
Saline Solution
1
Quality of Life
1
Observation
1
Magnesium Sulfate
1
Injections
1
Influenza Vaccines
1
Histocompatibility Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Exercise Therapy
1
Combined Modality Therapy
1
Cell- and Tissue-Based Therapy
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Mesothelioma
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled